The Union World Conference on Lung Health 2026

Rio de Janeiro, Brazil

As a leading global forum for advancing efforts to end tuberculosis and improve lung health, the Union Conference brings together researchers, health professionals, advocates and policymakers to share the latest evidence, innovations and experiences from across the world. It provides an important platform for shaping the global health agenda, strengthening collaboration and accelerating progress towards better prevention, diagnosis and treatment of TB and other lung diseases.

For Unitaid, the Union Conference is an opportunity to engage with partners, highlight progress in bringing innovative TB tools and approaches closer to the people who need them, and contribute to discussions on how to accelerate their introduction and access. Through our work with partners, we support efforts to make new and improved tools available, affordable and accessible, particularly in the countries and communities most affected by TB.

Unitaid booth: A shared space for community and civil society partners

Windsor Convention & Expo Center - Booth D333

17 November 2026
15:10 - 18:25 BRT

WHO Global #EndTB Symposium 2026

Windsor Convention & Expo Center - Asia II

With 2030 rapidly approaching, the WHO Global End TB Symposium 2026 will focus on the urgent actions needed to accelerate progress, strengthen political engagement, drive multisectoral action and translate global commitments into results, while harnessing the power of new innovations and breakthroughs to transform the fight against TB.
Bringing together countries, partners, civil society, affected communities, researchers and other stakeholders, the Symposium will present key findings from the newly released WHO Global Tuberculosis Report 2026, taking stock of the latest trends and progress towards global TB targets. It will also spotlight the latest advances and breakthroughs in TB prevention, diagnosis and treatment, and explore how innovations and new technologies can be rapidly and equitably translated into greater impact for people and communities affected by TB.
At this critical juncture, the Symposium will also look beyond 2030, providing a platform to discuss the priorities and transformative approaches that should shape the WHO post-2030 global TB strategy and the next era of the global TB response. The Symposium will call for renewed political leadership, sustained investment, stronger partnerships and multisectoral action to deliver on commitments, accelerate progress to 2030, and drive the transformative change needed to advance global efforts to end TB.

  • From breakthroughs to access: Delivering innovations at scale – Speaker: Cherise Scott
17 November 2026
15:00 - 18:00 BRT

Community action for active tuberculosis drug safety monitoring and management (CADSM): Hands on experience workshop

Windsor Convention & Expo Center - Segovia I/II
The rapid scale‑up of new and repurposed medicines for TB treatment has heightened the need for robust systems that ensure patient safety. As countries adopt novel drugs and treatment regimens, the ability to detect, report, assess, and manage adverse drug reactions (ADRs) becomes increasingly critical. Active TB Drug Safety Monitoring and Management (aDSM) offers a structured and proactive framework to support this process, particularly for high‑risk or innovative therapies.
While many countries have successfully introduced aDSM at the health‑facility level, community‑level engagement remains limited. This gap is significant: community health workers (CHWs), CSO, CBOs, treatment supporters, and patient groups are often the first to observe side effects or changes in patient wellbeing. Their proximity to patients positions them as essential contributors to early AE detection and timely referral. Greater community involvement in aDSM could promote the acceptability of new treatment regimens by identifying issues early before they have time to develop into recurring problems that limit demand for new regimens.Additionally, limited awareness on how and when to check for an adverse event, when to seek help, inadequate training, lack of tools, lack of standardized manner of AE detection and testing. weak linkages between community structures and formal pharmacovigilance units, stigma and fear of treatment discontinuation leads to underreporting of side effects.CADSM seeks to bridge the gap by empowering community actors to take an active role in drug safety surveillance. By equipping them with practical skills, user‑friendly tools, and the confidence to recognize and report AEs, CADSM strengthens the continuum of care from the community to the health facility. Through experience sharing, hands‑on learning, and collaborative problem‑solving, CADSM fosters a more inclusive, responsive, and patient‑centered drug safety monitoring and integrating community structures into national aDSM systems.
  • Chair: Chikosa Nwira
  • Speaker: Cherise Scott
19 November 2026
15:55 - 17:25 BRT

Phenotypic drug susceptibility testing for TB: From MIC data to decision-making in the genomic era

Windsor Convention & Expo Center - Americas II

Phenotypic drug susceptibility testing (pDST) remains the reference standard for defining drug resistance and guiding tuberculosis treatment, yet global capacity is declining and methods remain insufficiently standardized. Recent multi-country efforts to validate broth microdilution (BMD) platforms and generate minimum inhibitory concentration (MIC) data offer an opportunity to harmonize testing and interpretation. This symposium will position pDST as a critical complement to genomic testing, highlighting its role in defining resistance, supporting WHO mutation catalogue development, and informing treatment decisions. Through implementation- and evidence-focused presentations, including insights from clinical studies and global initiatives, speakers will identify key priorities to strengthen laboratory systems and support the future of DR-TB care.

Shaping the future of DR-TB care: The role of phenotypic DST in access, innovation and scale-up

This presentation will provide a global perspective on the role of phenotypic DST within evolving models of DR-TB care. It will highlight how investments in diagnostics, including standardized phenotypic methods, support access to new and repurposed drugs, guide treatment decisions, and strengthen health systems. Key priorities for scaling and sustaining DST capacity will be discussed, alongside opportunities to align innovation, implementation, and patient-centered care.
Speaker: Anisa  Ghadrshenas
17 November 2026
13:15 - 14:45 BRT

Scaling AI for TB elimination through access, affordability and impact

Windsor Convention & Expo Center - Oceania VI/VII

Organised by: DeepTek.ai
To bring together global health partners and national TB programmes to explore what it takes to move AI-powered TB screening from innovation to routine practice at scale. Through perspectives from market-shaping organizations and countries at different stages of AI adoption, the session will examine the practical enablers of equitable access—including affordability, financing, procurement, implementation, health system integration, and sustainable market mechanisms—and identify actionable strategies to accelerate the adoption of quality-assured AI technologies for TB elimination.

Catalysing equitable access to AI for TB: From innovation to sustainable scale

AI has demonstrated strong potential to improve TB detection and other lung conditions, but achieving population-level impact requires more than technological innovation. This presentation will explore how Unitaid’s catalytic investments, market-shaping interventions, and strategic partnerships can accelerate equitable access to quality-assured AI technologies while supporting sustainable adoption by national TB and lung-health programmes.

Speaker: Dessie Tarlton

18 November 2026
17:45 - 19:15 BRT

Towards 2030: Introducing and integrating next-generation innovations for resilient, people-centered tuberculosis care

Windsor Convention & Expo Center - Americas III

Organised by: PATH, Unitaid, World Health Organization, Global Coalition of TB Advocates
The global tuberculosis (TB) response is in a pivotal period. With new vaccine candidates and shorter treatment regimens on the horizon and decentralized diagnostics and AI-enabled technologies being introduced, the pipeline of TB innovations is rich and advancing rapidly. The challenge, however, lies in how countries can sustainably introduce, integrate, and scale these innovations to accelerate progress toward 2030 global targets while ensuring equitable and inclusive access to people-centered TB care.
Framed by an overview of progress towards 2030 targets and a state-of-play of emerging TB innovations, this session will convene government leaders, civil society, affected communities, researchers, funders, and implementers to share learnings on sustainably introducing product and service innovations through primary health care platforms and concluding with a dynamic discussion delving into challenges and practical solutions for community-driven and resilient roll out and scale of critical new tools and care models that accelerate people-centered approaches to end TB.

Innovation pipeline: what’s here, what’s coming and what that means for sustained access

A state-of-play on the current state of new TB products and technologies being rolled out and in the pipeline across vaccines, therapeutics, and diagnostics.

Speaker: Jérémie Piton

19 November 2026
14:15 - 15:45

Financing what matters: How countries can fund high-impact TB interventions at scale

Windsor Convention & Expo Center - Alhambra I/II

This session aims to move beyond a focus on innovative financing mechanisms to explore how countries can practically finance high-impact tuberculosis (TB) interventions at scale. It will focus on how financing decisions influence programme delivery, particularly for interventions such as active case finding, private sector engagement, diagnostics, and prevention, which are often underfunded within existing systems.
Background and Rationale:
Despite global commitments to end TB, many high-impact interventions remain underfunded or inconsistently financed. The challenge is not only the overall level of funding, but how resources are allocated within national programmes. Previous discussions on innovative financing have largely focused on instruments (e.g. development bank loans, debt swaps, philanthropy), with less attention to how these translate into programmatic decisions at country level. This session builds on that foundation and shifts the focus towards implementation, specifically how countries can align financing withi nterventions that drive impact.

Market stewardship during transitions

Speaker: Anisa Ghadrshenas
Learn more
Our work on tuberculosis
Related news